Cytokinetics (CYTK) versus Its Peers Financial Survey

Cytokinetics (NASDAQ:CYTK) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Cytokinetics to related businesses based on the strength of its earnings, risk, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider and Institutional Ownership

47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Cytokinetics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	19	0	2.86
Cytokinetics Competitors	9905	15274	45607	1595	2.54

Cytokinetics presently has a consensus target price of $106.67, suggesting a potential upside of 89.87%. As a group, “Biotechnology” companies have a potential upside of 99.47%. Given Cytokinetics’ peers higher probable upside, analysts clearly believe Cytokinetics has less favorable growth aspects than its peers.

Profitability

This table compares Cytokinetics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-686.63%	N/A	-48.26%
Cytokinetics Competitors	-12,285.98%	-196.04%	-30.61%

Valuation and Earnings

This table compares Cytokinetics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cytokinetics	$88.04 million	-$784.96 million	-9.30
Cytokinetics Competitors	$729.47 million	$11.46 million	-14.85

Cytokinetics’ peers have higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Cytokinetics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Cytokinetics’ peers have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Summary

Cytokinetics peers beat Cytokinetics on 8 of the 13 factors compared.

Cytokinetics Company Profile

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.